Sign In
Buy CGON
$71.19
-1.84 (-2.52%)
At Close: Jul 31, 2026
Kuehn Law Encourages Investors of CG Oncology, Inc. to Contact Law Firm
07:39pm, Wednesday, 29'th Jul 2026
NEW YORK, July 29, 2026 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of CG Oncology, Inc. ( NASDAQ : CGON) breached
CG Oncology Announces Publication of Pivotal Phase 3 BOND-003 Cohort C Study Results in The Lancet Oncology
06:45pm, Monday, 27'th Jul 2026
Data reinforce durable responses, bladder preservation, low rate of disease progression, and favorable safety and tolerability in patients with high-risk, BCG-unresponsive non-muscle invasive bladder
CG Oncology Stock Gains 12% in Three Months: What's Driving It?
10:07am, Monday, 13'th Jul 2026
CGON climbs as cretostimogene nears a planned 2026 BLA filing, posts encouraging phase II data. It maintains a cash position that supports operations through 2029.
CG Oncology Eyes Bladder Cancer Breakthrough With Phase 3 Data, Q4 Filing Ahead
03:02am, Wednesday, 10'th Jun 2026
CG Oncology NASDAQ: CGON Chief Executive Officer Arthur outlined the company's upcoming clinical and regulatory milestones for cretostimogene during a presentation at the Goldman Sachs Global Healthca
CG Oncology, Inc. (CGON) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
05:52pm, Tuesday, 09'th Jun 2026
CG Oncology, Inc. (CGON) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
CG Oncology Touts Cretostimogene Data, BLA Progress in Bladder Cancer Push
05:06pm, Sunday, 07'th Jun 2026
CG Oncology NASDAQ: CGON is focused on advancing cretostimogene, an oncolytic immunotherapy for non-muscle invasive bladder cancer, Chief Executive Officer Arthur Kuan said during a discussion at the
CG Oncology to Present at Upcoming Investor Conferences in June
04:05pm, Thursday, 28'th May 2026
DALLAS, May 28, 2026 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON) today announced that Arthur Kuan, Chairman, President & Chief Executive Officer, will participate in fireside chat presentatio
CG Oncology Touts Bladder Cancer Data, Q4 Filing Plans at RBC Conference
10:05pm, Wednesday, 20'th May 2026
CG Oncology NASDAQ: CGON executives used an RBC Capital Markets fireside chat to outline recent clinical data for cretostimogene, the company's investigational therapy for non-muscle invasive bladder
Patrick Hensley, MD and Daniel Joyce, MD, MS each received a grant up to $50,000.00 to support the development of outstanding clinical cancer research to improve the treatment of NMIBC Last year's awa
- High CR rates at any time observed in the CIS-containing population with 85.7% and 92.3% in the ITT population and Efficacy Evaluable population, respectively
CG Oncology BLA Filing on Track as Key Bladder Cancer Data Nears
03:09am, Friday, 15'th May 2026
CG Oncology NASDAQ: CGON executives said the company remains on track to complete a rolling biologics license application for cretostimogene in BCG-unresponsive high-risk non-muscle invasive bladder c
CG Oncology, Inc. (CGON) Presents at Bank of America Global Healthcare Conference 2026 Transcript
04:21pm, Tuesday, 12'th May 2026
CG Oncology, Inc. (CGON) Presents at Bank of America Global Healthcare Conference 2026 Transcript
CG Oncology's Presence at American Urological Association (AUA) Annual Meeting Underscores its Strong Commitment to NMIBC
04:15pm, Monday, 11'th May 2026
-First results from CORE-008 Cohort CX Phase 2 Trial evaluating intravesical combination therapy in High-Risk BCG-Exposed and BCG-Unresponsive patients to be presented-
CG Oncology Analysts Boost Their Forecasts Following Q1 Earnings
12:40pm, Monday, 11'th May 2026
CG Oncology (NASDAQ:CGON) reported mixed results for the first quarter on Friday.
CG Oncology, Inc. (CGON) Reports Q1 Loss, Tops Revenue Estimates
10:36am, Friday, 08'th May 2026
CG Oncology, Inc. (CGON) came out with a quarterly loss of $0.71 per share versus the Zacks Consensus Estimate of a loss of $0.58. This compares to a loss of $0.45 per share a year ago.
